TY - JOUR
T1 - The Potential of F-18 Flurpiridaz PET/CT Myocardial Perfusion Imaging for Precision Imaging
AU - Patel, Krishna K.
AU - Singh, Annapoorna
AU - Bateman, Timothy M.
N1 - Funding Information:
Dr. Bateman receives research grant support from Bracco, Jubilant Drax Image, Spectrum Dynamics, and GE Healthcare. He serves as a consultant to AIM, AstraZeneca, Curium, and GE Healthcare. He has an equity interest in Cardiovascular Imaging Technologies. He has intellectual property rights for Imagen PET and SPECT software. The other authors have no disclosures.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/8
Y1 - 2022/8
N2 - Purpose of the Review: Myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) has been the main method for assessing patients with known or suspected coronary artery disease (CAD) for decades. Based on a strong and growing evidence base, positron emission tomography (PET) MPI is increasingly favored when it is available. However, currently available PET perfusion tracers have limitations that have hampered broad utilization. Recent Findings: F-18 flurpiridaz is a novel PET MPI agent that is nearing completion of studies necessary to obtain regulatory approval. It has unique capabilities that will facilitate further expansion of PET MPI utilization. In addition, it has characteristics that may define it as the best MPI agent to date, in terms of the potential to equalize accuracy independent of patient size, gender, complexity, or ability to perform exercise stress. Summary: The combination of excellent image quality and accurate absolute blood flow quantification hold the potential of its being an ideal precision tool for non-invasive assessment of myocardial blood flow and entire spectrum of ischemic heart disease.
AB - Purpose of the Review: Myocardial perfusion imaging (MPI) with single photon emission computed tomography (SPECT) has been the main method for assessing patients with known or suspected coronary artery disease (CAD) for decades. Based on a strong and growing evidence base, positron emission tomography (PET) MPI is increasingly favored when it is available. However, currently available PET perfusion tracers have limitations that have hampered broad utilization. Recent Findings: F-18 flurpiridaz is a novel PET MPI agent that is nearing completion of studies necessary to obtain regulatory approval. It has unique capabilities that will facilitate further expansion of PET MPI utilization. In addition, it has characteristics that may define it as the best MPI agent to date, in terms of the potential to equalize accuracy independent of patient size, gender, complexity, or ability to perform exercise stress. Summary: The combination of excellent image quality and accurate absolute blood flow quantification hold the potential of its being an ideal precision tool for non-invasive assessment of myocardial blood flow and entire spectrum of ischemic heart disease.
KW - Flurpiridaz
KW - Ischemic heart disease
KW - Myocardial perfusion imaging
KW - Positron emission tomography
KW - Precision imaging
UR - http://www.scopus.com/inward/record.url?scp=85130719574&partnerID=8YFLogxK
U2 - 10.1007/s11886-022-01713-5
DO - 10.1007/s11886-022-01713-5
M3 - Review article
AN - SCOPUS:85130719574
SN - 1523-3782
VL - 24
SP - 987
EP - 994
JO - Current Cardiology Reports
JF - Current Cardiology Reports
IS - 8
ER -